Enhanced CAR-T Cell Preparation and Therapy System

An integrated system for preparing CAR-T cells with TCM as the main active component, featuring improved yield, specificity, safety, and efficacy through advanced detection, isolation, and modification techniques.

The original patent, 'Method for preparing CAR-T cell with TCM as main active component and use thereof', has limitations in terms of yield, specificity, and safety. The new inventive concept addresses these limitations by introducing a system that incorporates advanced detection, isolation, and modification techniques to improve the preparation and therapy of CAR-T cells.

The new system comprises a device for detecting and isolating CD45RO+/CD197+ surface markers on the TCM cells, thereby increasing the yield of TCM cells. The system also involves modifying the antigen-binding domain of the CAR to recognize a specific tumor-associated antigen, reducing off-target effects. Additionally, the extracellular domain of the CAR is modified to include a targeting moiety that specifically binds to a tumor-associated antigen, improving the efficacy of the CAR-T cells. Furthermore, a suicide gene is incorporated into the CAR-T cells, which can be activated in response to adverse effects, reducing the risk of toxicity. The system also features a microfluidic device for isolating and expanding TCM cells based on their surface markers, increasing the purity and yield of TCM cells.

The new claims introduce novel and non-obvious improvements to the original patent, including the integration of advanced detection, isolation, and modification techniques to improve the preparation and therapy of CAR-T cells. The inventive step lies in the combination of these techniques to create an integrated system that addresses the limitations of the original patent.

Alternative embodiments of the inventive concept could include using different surface markers for detection and isolation, or modifying the CAR-T cells to target different tumor-associated antigens. Variations could also include using different microfluidic devices or incorporating additional safety features.

The enhanced CAR-T cell preparation and therapy system has significant commercial potential in the field of cancer treatment, particularly in the development of targeted immunotherapies. The system could be marketed to pharmaceutical companies, research institutions, and hospitals, offering a more efficient and effective way to prepare and administer CAR-T cell therapy.